Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 214

AWESOME.

New UCLA research suggests that a gene-based immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS.

In a study to be published in an August issue of the bi-monthly peer-reviewed Journal of Virology, researchers with the UCLA AIDS Institute and Center for AIDS Research found that recently discovered potent antibodies can be used to generate chimeric antigen receptors, or CARs, that can be used to kill cells infected with HIV-1.

CARs are artificially created immune T-cells that have been engineered to produce receptors on their surface that are designed to target and kill specific cells containing viruses or tumor proteins. The use of these chimeric receptors is currently the focus of gene immunotherapy against cancer, but they could also be used to create a strong immune response against HIV, said Dr. Otto Yang, professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA and the study’s corresponding author.

Read more

A Yale research team has designed a system to modify multiple genes in the genome simultaneously, while also minimizing unintended effects. The gene-editing “toolbox” provides a user-friendly solution that scientists can apply to research on cancer and other disciplines, according to a news release from Yale.

The study was published on July 26 in Nucleic Acids Research.

The news release states that, with modern genetic engineering techniques, researchers can edit genes in experiments. This allows researchers to study important disease-related genes and may ultimately allow them to treat genetic diseases by making edits in specific sites of the human genome. However, progress has been hampered by several challenges, including the editing of unintended sites — referred to as off-target effects.

Read more

Hmmm.

We can rebuild him; we have the technology—but Americans question if we should in a new survey designed to assess attitudes to modern biotechnology advances.

A new report, based on a survey of 4,700 U.S. adults coming out of the Pew Research Center, looked at a range of views on certain advances in biology, with opinions split on the ethics and long-term problems associated with enhancing human capacity.

When asked about gene editing, the majority of those surveyed, 68%, said they would be “very” or “somewhat” worried about its implications.

Continue reading “U.S. wary on biotech advances; gene editing, CRISPR ‘raising urgency’” | >

On the path towards Singularity — I believe that this is an individual choice. However, to remain relevant and competitive in industry we may see a day when folks will require this type of enhancement to compete, perform in military operations, etc.

The researchers carried out a survey of more than 4,700 US adults.

The survey asked the public on views of gene editing, implantation of brain chips, and transfusions of synthetic blood.

Continue reading “Most people are too scared to use brain chips and synthetic blood to improve performance” | >

The public was unenthusiastic on all counts, even about protecting babies from disease.

Americans aren’t very enthusiastic about using science to enhance the human species. Instead, many find it rather creepy.

A new survey by the Pew Research Center shows a profound distrust of scientists, a suspicion about claims of progress and a real discomfort with the idea of meddling with human abilities. The survey also opens a window into the public’s views on what it means to be a human being and what values are important.

Pew asked about three techniques that might emerge in the future but that are not even close to ready now: using gene editing to protect babies from disease, implanting chips in the brain to improve people’s ability to think, and transfusing synthetic blood that would enhance performance by increasing speed, strength and endurance.

Continue reading “Building a Better Human With Science? The Public Says, No Thanks” | >

I never get tired of hearing more information on this research.

A synthetic genetic circuit programmed into an attenuated Salmonella enterica subspecies can be used to systemically deliver an anti-tumor toxin into mice with cancer. The circuit allows the bacterial cells inside a tumor to synchronously self-destruct by lysis, releasing the toxin directly in the tumor.

Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs.

“This impressive study represents a big step towards one of the great dreams of synthetic biology: rationally programming cells, in this case bacteria, to exhibit complex, dynamic, and beneficial behaviors in a host organism,” Michael Elowitz, whose Caltech lab builds synthetic genetic circuits and who was not involved in the work, wrote in an email to The Scientist.

Continue reading “Engineered bacteria deliver an anti cancer tumor toxin in mice before self-destructing” | >

(Medical Xpress)—A team of researchers at Sichuan University’s West China Hospital has announced plans to begin a clinical trial where cells modified using the CRISPR gene editing technique will be used on human beings for the very first time. They plan to edit genes in such a way as to turn off a gene that encodes for a protein that has been shown by prior research to slow an immune response and by so doing treat patients with lung cancer.

The CRISPR has been in the news a lot of late as scientists creep ever closer to using it as a means to treat diseases or to change the very nature of biological beings. China has been a leader in promoting such research on human beings—they were the first to use the technique to on human embryos.

This new effort is seen as far less controversial—a team in the U.S. is planning a similar study as soon as they can get regulators to greenlight their project. The Chinese team plans to retrieve T cells from patients that have incurable and then edit the genes in those cells. More specifically, they will be looking to disable a gene that encodes for a protein called PD-1—prior research has shown that it acts as a brake on an to help prevent attacks on healthy cells. Once the cells have been edited and inspected very carefully to make sure there were no editing errors they will be allowed to multiply and then all of the cells will be injected back into the same patient’s bloodstream. It is hoped that the edited cells will cause the immune system to mount a more aggressive attack on , killing them and curing the patient.

Read more

Perfecting Synthetic biology — this definitely is advancement forward in the larger Singularity story.

In both higher organisms and bacteria, DNA must be segregated when cells divide, ensuring that the requisite share of duplicated DNA goes into each new cell. While previous studies indicated that bacteria and higher organisms use quite different systems to perform this task, A*STAR researchers have now found a bacterium that uses filaments with key similarities to those in multicellular organisms, including humans.

Robert Robinson from the A*STAR Institute of Molecular and Cell Biology has a long-standing interest in what he calls the “biological machines” that move DNA around when cells divide. He and his co-workers had gleaned from gene sequencing analysis that there was something distinctive about the DNA-moving machinery in the bacterium Bacillus thuringiensis.

Along with an international team of colleagues, the A*STAR researchers used electron microscopy and biochemical analysis to investigate the way small circular strands of DNA called plasmids moved in this bacterium. They identified a novel form of bacterial filament that combines to form tubules with some similarities to the microtubules observed in higher organisms. Bacterial systems previously studied also use protein filaments to move DNA, but they do not share such obvious similarities to those of higher organisms. The new-found similarity in Bacillus thuringiensis is of great interest from an evolutionary perspective as it suggests that evolution has furnished at least some bacteria and with different machineries but similar methods to manipulate DNA.

Continue reading “Proteins that move DNA around in a bacterium are surprisingly similar to those in our own cells” | >

Beautiful.

Researchers at the University of California San Diego and the Massachusetts Institute of Technology (MIT) have come up with a strategy for using synthetic biology in therapeutics. The approach enables continual production and release of drugs at disease sites in mice while simultaneously limiting the size, over time, of the populations of bacteria engineered to produce the drugs. The findings are published in the July 20 online issue of Nature.

UC San Diego researchers led by Jeff Hasty, a professor of bioengineering and biology, engineered a clinically relevant bacterium to produce and then self-destruct and release the drugs at the site of tumors. The team then transferred the bacterial therapy to their MIT collaborators for testing in an animal model of colorectal metastasis. The design of the therapy represents a culmination of four previous Nature papers from the UC San Diego group that describe the systematic development of engineered genetic clocks and synchronization. Over the years, the researchers have employed a broad approach that spans the scales of synthetic biology.

Continue reading “Synthetic biology used to limit bacterial growth and coordinate drug release” | >